Medistim ASA (MEDI.XOSL) DCF Valuation
Every assumption below is yours to change. The defaults are derived from this company's own filing history, not from a house view.
Conservative
kr 111.43
59% overvaluedvs kr 275.00
Base
kr 142.37
48% overvaluedvs kr 275.00
Optimistic
kr 177.87
35% overvaluedvs kr 275.00
Where today's price sits
Today's price falls outside the modelled range.
Verdict
Today's price sits above all three scenarios. Under these assumptions the stock looks overvalued, so either the growth inputs are too conservative or the price is ahead of the cash flows.
Base free cash flow
kr 153M
Trailing twelve months
Historical FCF CAGR
+5.7%
Across 6 reported periods
Market implies
12.2%
Growth needed at 8% WACC
Terminal value share
60%
Of the base case valuation
Growth needed to justify today's price
At a 8.0% discount rate, today's price already assumes 12.2% annual free cash flow growth for ten years. Your base case assumes 5.7%, so the market is paying for growth you are not forecasting.
Curve holds terminal growth at 2.5%, years 6 to 10 at half the first-stage rate, and applies no safety margin.
Free cash flow history
The most recent period is the base every projection starts from. Compounded, that history is +5.7% a year.
Medistim ASA (MEDI.XOSL) DCF: intrinsic value and margin of safety
Intrinsiqq's two-stage DCF values Medistim ASA (MEDI.XOSL) at about NOK 189.52 per share, or NOK 142.14 with a 25% margin of safety. At NOK 275.00 the stock looks overvalued. Every assumption is adjustable below; this is analysis, not investment advice.
Frequently asked
What is Medistim ASA's (MEDI.XOSL) fair value?+
Intrinsiqq's two-stage discounted cash flow (DCF) model estimates an intrinsic value of about NOK 189.52 per share for MEDI.XOSL. It projects recent free cash flow forward at a growth rate that fades toward a long-run rate, then discounts those cash flows back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around NOK 142.14. The output moves with the growth and discount-rate inputs, so it is best read as a range, not a single number. You can change every assumption with the sliders on this tab.
Is Medistim ASA overvalued based on a DCF?+
At NOK 275.00, MEDI.XOSL trades above the base-case intrinsic value of about NOK 189.52, a 31.1% premium over that estimate, so on this model it looks overvalued. A DCF is only one lens: a premium can be justified if the business grows faster or is higher quality than the base case assumes, which is exactly what the sliders let you test.
What growth is priced into Medistim ASA?+
The base case grows MEDI.XOSL's free cash flow at about 5.7% a year before fading, against roughly 5.7% historical free-cash-flow growth. If the price implies growth well above what the company has actually delivered, the market is paying for optimism; if below, expectations are modest. Adjust the growth assumption on this tab to see what the current price is really betting on.
What is a good margin of safety for Medistim ASA?+
A margin of safety is the discount to intrinsic value you demand before buying, to protect against being wrong on the inputs. Intrinsiqq applies 25% by default, which turns MEDI.XOSL's NOK 189.52 intrinsic estimate into a NOK 142.14 entry. Wider margins suit less predictable businesses; you can set your own on this tab. This is analysis from company filings, not investment advice.
Related stocks: Medical Devices
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.